QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

PLSE

QT49Pulse Biosciences, Inc.
NASDAQ·Healthcare·Medical - Instruments & Supplies·USA
Latest market price
25.60
+0.15+0.59%
OverviewShort InterestFilings
PLSEQT49Pulse Biosciences, Inc.·NASDAQ
OverviewShort InterestFilings
25.60+0.59%
TA
Loading chart...
Screen all →
BDX+1.67%$143.98ALC+0.84%$64.68MDLN-1.32%$35.94WST+1.35%$327.95COO+1.32%$65.91BAX+2.58%$19.89ATR+0.28%$120.32RGEN-1.15%$132.02
Snapshot
Index-P/E-EPS (ttm)-
Insider Own-
Shs Outstand69.21M
Perf Week-4.80%
Market Cap1.76BForward P/E-EPS next Y-1.20Insider Trans2.02%Shs Float-Perf Month2.61%
Enterprise Value1.70BPEG2.18EPS next Q-0.31Inst Own-Short Float-Perf Quarter14.29%
Income-76091913.00P/S2345.39EPS this Y-Inst Trans-Short Ratio-Perf Half Y79.90%
Sales751.00KP/B26.02EPS next Y-4.96%ROA-91.36%Short Interest-Perf YTD86.45%
Book/sh0.95P/C-EPS next 5Y-ROE-86.67%52W High28.53 -10.27%Perf Year70.21%
Cash/sh0.98P/FCF-EPS past 3/5Y-ROIC-106.25%52W Low12.56 103.82%Perf 3Y-
Dividend Est.-EV/EBITDA-22.95Sales past 3/5Y-Gross Margin-91.08%Volatility5.39% 4.86%Perf 5Y-
Dividend TTM-EV/Sales2263.95EPS Y/Y TTM-19.57%Oper. Margin-10392.14%ATR (14)1.82Perf 10Y-
Dividend Ex-Date-Quick Ratio7.24Sales Y/Y TTM-Profit Margin-9929.03%RSI (14)53.40Recom2.50
Dividend Gr. 3/5Y-Current Ratio7.26EPS Q/Q-58.82%SMA200.97%Beta2.33Target Price30.67
Payout0.00%Debt/Eq0.11Sales Q/Q-SMA509.88%Rel Volume1.13Prev Close25.45
Employees75LT Debt/Eq0.07EarningsAug 11SMA20037.49%Avg Volume321.29KPrice25.60
IPO DateMay 18, 2016Option/ShortYes / YesEPS/Sales Surpr.15.63% -Net Debt/EBITDA0.83Volume364,270Change0.59%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-04-26InitiatedCanaccordBuy$32
Feb-20-26ReiteratedOppenheimer$22 → $30
Feb-06-26ReiteratedMizuho Securities$25 → $30
Jan-30-26InitiatedMizuhoOutperform$25
Sep-21-22DowngradeMaxim GroupBuy → Hold
May-13-22DowngradeHC Wainwright & Co.Buy → Neutral
May-12-20UpgradeH.C. WainwrightNeutral → Buy
May-12-20UpgradeHC Wainwright & Co.Neutral → Buy
Feb-14-20DowngradeH.C. WainwrightBuy → Neutral
Feb-14-20DowngradeHC Wainwright & Co.Buy → Neutral
Latest News
Jun-10-26
Jun-10-2606:12PM
Pulse Biosciences, Inc. (PLSE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A201
Gross Profit-10-1
Selling, General and Administrative Excl. Other322416
Research and Development453228
Other Operating Expense-10-2
Operating Income-77-56-44
Interest Expense001
Unusual Expense
———
Non-Operating Income (Expense)-4-3-2
Net Income Before Taxes-73-54-42
Income Taxes
000
Consolidated Net Income-73-54-42
Net Income From Continuing Operations-73-54-42
Net Income-73-54-42
EPS (Recurring)-1.08-0.92-0.88
EPS (Basic, Before Extraordinaries)-1.08-0.92-0.88
EPS (Diluted)-1.08-0.92-0.88
EBITDA-72-52-40
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin———
Operating Margin———
Net Margin———
Shares Outstanding675848
Market Capitalization920——
Operating Lease Expense
———
Insider Trading Volume
$27.56$25.11$22.66$20.22$17.77● Close Price0.00M6.65M13.30M19.94M26.59MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
DUGGAN ROBERT Wdirector, 10 percent owner:May 11 '26Buy19.691,320,46625,999,97648,370,047May 15 12:00 AM
LAVIOLETTE PAUL AChief Executive OfficerMay 11 '26Buy19.6930,000590,70015,846May 11 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 18 '26Option Exercise1.5310,00015,300300,000Feb 23 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 18 '26Sale23.645,000118,20043,298Feb 23 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 17 '26Sale23.6320,000472,60043,298Feb 17 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 17 '26Option Exercise1.5340,00061,200305,000Feb 17 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 13 '26Sale23.5320,000470,60043,298Feb 17 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 13 '26Option Exercise1.5320,00030,600325,000Feb 17 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 12 '26Sale23.3720,000467,40043,298Feb 17 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 12 '26Option Exercise1.5320,00030,600345,000Feb 17 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 11 '26Sale25.2020,000504,00043,298Feb 11 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 11 '26Option Exercise1.5340,00061,200365,000Feb 11 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 10 '26Option Exercise1.5320,00030,600385,000Feb 11 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 10 '26Sale23.5220,000470,40043,298Feb 11 12:00 AM
Danahy Kevin PatrickChief Commercial OfficerFeb 09 '26Sale21.4520,000429,00043,298Feb 11 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR